| Name | Title | Contact Details |
|---|
The Investor Relations website contains information about Cingulate Incs business for stockholders, potential investors, and financial analysts.
Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of end stage kidney disease (ESKD). Pathalys` initial asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of SHPT in hemodialysis patients. Beyond upacicalcet, Pathalys continues to identify other high priority needs and potential solutions for patients with ESKD. Pathalys is headquartered in Research Triangle Park, North Carolina.
Chartiers’ primary focus is the integration of physical health and mental health wellness to enhance the quality of life for all people with behavioral or intellectual/ and developmental disabilities. Chartiers operates programs for adults with inte...